Immunology:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • HOME

      RINVOQ AD

      HUMIRA

      SKYRIZI

      SKINVERSATIONS

      SERVICES

      CONTACT

      » Summary

      decorative
      Video

      DURABILITY

      SUSTAINED PASI RESPONSE AND PsA SYMPTOM CONTROL 1,2†

      †Over 52 weeks

      In patients with PsO treated with SKYRIZI®  (UltIMMa-1 and
      UltIMMa-2):1,2

      • 75% of patients achieved PASI 90 at Week 16
      • >80% achieved PASI 90 at Week 52
      • Twice the rate of PASI 100 response at Week 52 with SKYRIZI® vs ustekinumab in both UltIMMa studies
        - SKYRIZI®: 56 - 60%*
        - Ustekinumab: 21 - 30%

      *P<0.0001 vs ustekinumab.

      In patients with PsA treated with SKYRIZI® (KEEPSAKE-1 and KEEPSAKE-2):4–7

      • ≥51.3% and >58.5% achievement of ACR20 at Week 24 and Week 52, respectively, regardless of prior biologic experience4–7
      Learn more
      decorative
      Video

      SIMPLICITY

      ONLY 4 DOSES PER YEAR1*

      *Following induction dose

      • SKYRIZI® is dosed 150 mg at Week 0, Week 4 and every 12 weeks thereafter1
      • Dose adjustment not required, regardless of patient subgroup1-3‡

      ‡Clinically meaningful changes in efficacy and safety of SKYRIZI® were not observed with increased body weight, therefore no dose adjustment is necessary based on body weight.

      Learn more
      decorative
      Video

      SAFETY

      SAFETY PROFILE COMPRISING MORE THAN 3,500 PsO AND PsA PATIENTS1#

      #PsO: n=2234; PsA: n=1365

      • The most common adverse events included respiratory tract infection (viral, bacterial or unspecified), sinusitis (including acute), rhinitis, nasopharyngitis, pharyngitis (including viral) and tonsillitis1
      • For PsO patients exposed to a maximum of 224 weeks of SKYRIZI®, the rates of serious AEs, AEs leading to discontinuation and AEs of special interest remained comparable with the rates observed in the clinical development program8,9
      • PsA safety profile is consistent with the safety profile observed in PsO1
      Learn more

      » Real patient. Real SKYRIZI® results1,2

      decorative

      Patient depicted was a participant in the UltIMMa-2 pivotal trial undergoing continuous treatment with SKYRIZI®. Measurements were taken at each time point prior to administration of the next dose.1,2

      Baseline PSI
      week 4
      week 16
      week 52

      Note: The images above may not be indicative of all patients treated with SKYRIZI®

      PBS Information

      SKYRIZI: Authority required for the treatment of adults with severe plaque psoriasis. SKYRIZI is not listed on the PBS for the treatment of psoriatic arthritis. Refer to PBS Schedule for full authority information.

      Please review the full Product Information (PI) before prescribing, available below.

      SKYRIZI PI

      Abbreviations: AE, adverse event; ACR, American College of Rheumatology; PASI, Psoriasis Area Severity Index; PsA, psoriatic arthritis; PsO, psoriasis.

      References: 1. SKYRIZI Approved Product Information. 2. Gordon KB et al. Lancet 2018;392(10148):650–661. 3. Strober B et al. J Eur Acad Dermatol Venereol 2020;34(12):2830-2838. 4. Kristensen LE et al. Ann Rheum Dis 2022;81(2):225–31. 5. Kristensen LE et al. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 52-Week Results From KEEPsAKE 1. Poster presented at the Fall Clinical Dermatology Conference (FC21), October 21–24, 2021, Las Vegas, Nevada, Hybrid Meeting. 6. Östör A et al. Ann Rheum Dis 2022;81(3):351–8. 7. Östör A et al. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 52-Week Results From KEEPsAKE 2. Poster presented at the Fall Clinical Dermatology Conference (FC21), October 21–24, 2021, Las Vegas, Nevada, Hybrid Meeting. 8. Papp KA et al. Efficacy and Safety of Continuous Risankizumab Every 12 Weeks Beyond 3 Years of Follow-Up: An Interim Analysis of the LIMMitless Open-Label Extension Trial. Poster presented at: American Academy of Dermatology (AAD) 2021 VMX Event, April 23–25, 2021. 9. Papp KA et al. Dermatol Ther (Heidelb) 2021;11:487–497.

      AU-SKZD-210066. October 2024